Free Trial

Cronos Group (CRON) Competitors

Cronos Group logo
$2.04 +0.04 (+2.00%)
Closing price 07/3/2025 03:16 PM Eastern
Extended Trading
$2.04 0.00 (-0.25%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRON vs. MLTX, MOR, CRNX, VKTX, ALVO, CPRX, HCM, IMVT, OGN, and MIRM

Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Immunovant (IMVT), Organon & Co. (OGN), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

Cronos Group vs. Its Competitors

Cronos Group (NASDAQ:CRON) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Cronos Group has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a consensus price target of $74.50, suggesting a potential upside of 60.68%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MoonLake Immunotherapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cronos Group has a net margin of 39.69% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.69% -0.07% -0.07%
MoonLake Immunotherapeutics N/A -30.81%-28.40%

Cronos Group has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$117.61M6.69$41.08M$0.1315.69
MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.16

In the previous week, Cronos Group and Cronos Group both had 2 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.82 beat Cronos Group's score of 0.46 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MoonLake Immunotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cronos Group and MoonLake Immunotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

MetricCronos GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$786.79M$2.43B$5.54B$9.05B
Dividend YieldN/A1.78%5.24%4.03%
P/E Ratio15.698.9827.4320.23
Price / Sales6.69682.84420.79118.64
Price / Cash4,384.08158.5936.8958.07
Price / Book0.704.588.045.67
Net Income$41.08M$31.34M$3.18B$249.13M
7 Day Performance7.37%3.25%2.88%3.28%
1 Month Performance6.81%7.08%3.69%5.56%
1 Year Performance-8.52%0.17%36.15%21.12%

Cronos Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
2.2936 of 5 stars
$2.04
+2.0%
N/A-12.1%$786.79M$117.61M15.69450News Coverage
MLTX
MoonLake Immunotherapeutics
2.1822 of 5 stars
$44.87
+3.1%
$78.71
+75.4%
+9.9%$2.87BN/A-19.512News Coverage
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730News Coverage
CRNX
Crinetics Pharmaceuticals
3.5622 of 5 stars
$29.91
-0.8%
$74.56
+149.3%
-32.4%$2.80B$760K-7.83210
VKTX
Viking Therapeutics
4.366 of 5 stars
$24.86
-4.4%
$87.15
+250.6%
-44.2%$2.79BN/A-21.6220Trending News
Insider Trade
Gap Up
ALVO
Alvotech
3.5284 of 5 stars
$9.13
-2.4%
$18.00
+97.2%
-24.4%$2.75B$491.98M24.681,032
CPRX
Catalyst Pharmaceuticals
4.9248 of 5 stars
$22.12
-1.6%
$32.83
+48.4%
+41.3%$2.70B$491.73M14.0980
HCM
HUTCHMED
1.656 of 5 stars
$15.21
+2.5%
$19.00
+24.9%
-9.3%$2.65B$630.20M0.001,811
IMVT
Immunovant
1.4309 of 5 stars
$15.47
-2.1%
$38.33
+147.8%
-35.9%$2.64BN/A-5.65120
OGN
Organon & Co.
4.8936 of 5 stars
$9.82
+0.7%
$18.00
+83.3%
-50.4%$2.55B$6.40B3.414,000Trending News
MIRM
Mirum Pharmaceuticals
3.7416 of 5 stars
$50.28
-0.1%
$65.50
+30.3%
+47.4%$2.49B$336.89M-31.23140News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:CRON) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners